This study is about understanding the use of a drug called **dapagliflozin** for adults with **Chronic Kidney Disease (CKD)**. CKD is when the kidneys have trouble working well for more than 3 months. Dapagliflozin is a medicine that helps kidneys function better. The study looks at how dapagliflozin is used in real life, outside of controlled experiments. It will collect information from medical records in seven countries in Central Eastern Europe.

**Key Points:**

• The study lasts up to 12 months, collecting data from past medical records.
• No extra visits or tests are needed, as the study uses existing data.
• Participants must be adults with CKD starting dapagliflozin treatment.

Researchers want to know how many people use dapagliflozin, who they are, and how well the treatment works. They will not perform any new tests or treatments. If you just started using dapagliflozin, you might be eligible to join the study. It aims to help doctors and patients better understand CKD treatments in real-world settings.